ADA Medical moves into preclinical research

The Toronto-based research group ADA Medical announced Feb. 14 that it would be collaborating with Ephoran Multi-Imaging Solutions in Turin, Italy, to provide preclinical imaging services.

The partnership is set to focus on preclinical drug development in the areas of cardiovascular, oncology and inflammatory disease. AMA Medical will be building out preclinical contract services based on Ephoran Multi-Imaging Solution’s imaging technology and operations will roll out from Ephoran’s facilities at Bioindustry Park Silvano Fumero in Turin.

“Ephoran’s molecular imaging expertise will bring a much needed new technology to the market to assist drug and biotech companies in expediting cost-effective development of new compounds to clinical trials,” remarked ADA Medical CEO Renzo DiCarlo.

AMA intends to model and evaluate pharmaceuticals research by managing new drug development projects including all the involved pharmacokinetics, data management and quality assurance for a range of services, but especially for product testing in preparation for investigational new drug application.

“We are excited to see our technology be a part of ADA Medical’s medical research family,” said said Vito Lorusso, vice president of Ephoran. “Imaging technology provides significant biological data that will be used to verify the efficacy of a drug compound and make the drug development process much more effective and quicker.”